Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: An experimental study

Multidisciplinary Respiratory Medicine

Volumn 8, Issue 1, 2013, Pages

  Araz, Omer ^a   Demirci, Elif ^a   Ucar, Elif Yilmazel ^a   Calik, Muhammet ^a   Pulur, Didem ^b   Karaman, Adem ^a   Yayla, Muhammed ^a   Altun, Eren ^a   Halici, Zekai ^a   Akgun, Metin ^c  

^a ATATURK UNIVERSITY   (Turkey)

^b Zonguldak Government Hospital   (Turkey)

^c Yakutiye Medical Research Center Chest Disease Department   (Turkey)

Author keywords

Acute lung injury; Bosentan; Dexamethasone

Indexed keywords

BOSENTAN; DEXAMETHASONE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; SODIUM CHLORIDE;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL STUDY; HISTOPATHOLOGY; LUNG ALVEOLUS WALL; LUNG CONGESTION; LUNG EMPHYSEMA; LUNG HEMORRHAGE; LYMPHOCYTIC INFILTRATION; MALE; MONONUCLEAR CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; RAT; RESPIRATORY TRACT PARAMETERS; VASODILATATION;

EID: 84983158147     PISSN: 1828695X     EISSN: 20496958     Source Type: Journal    
DOI: 10.1186/2049-6958-8-74     Document Type: Article

References (31)

1. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993, 328:1471-1477.
2. Parrish WR, Gallowitsch-Puerta M, Czura C.J., Tracey KJ: Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Ann NY Acad Sci 2008, 1144:210-236.
3. Matot I, Sprung CL: Definition of sepsis. Intensive Care Med 2001, 27:3-9.
4. Remick DG: Pathophysiology of sepsis. Am J Pathol 2007, 170:1435-1444.
5. Griffiths B, Anderson ID: Sepsis, SIRS and MODS. Surgery 2009, 27:446-449.
6. Terblanche M, Almog Y, Rosenson R.S., Smith TS, Hackam DG: Statins: panacea for sepsis? Lancet Infect Dis 2006, 6:242-248.
7. Angus DC, Linde-Zwirble WT, Lidicker J., Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310
8. Guo R, Ward PA: Role of oxidants in lung injury during sepsis. Antioxid Redox Signal 2007, 9:1991-2002.
9. The ARDS, Network Authors for the ARDS Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000, 342:1301-1308
10. Leaver SK, Evans TW: Acute respiratory distress syndrome. BMJ 2007, 335:389-394.
11. Suter PM: Lung inflammation in ARDS-friend or foe? N Engl J Med 2006, 354:1739-1742.
12. Agarwal R, Nath A, Aggarwal A.N., Gupta D: Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 2007, 12:585-590.
13. Meduri GU, Marik PE, Chrousos G.P., Pastores SM, Arlt W, Beishuizen A, Bokhari F., Zaloga G, Annane D: Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008, 34:61-69.
14. Fagan KA, McMurtry IF, Rodman DM: Role of endothelin-1 in lung disease. Respir Res 2001, 2:90-101
15. Fujitani Y, Trifilieff A, Tsuyuki S., Coyle AJ, Bertrand C: Endothelin receptor antagonists inhibit antigen-induced lung inflammation in mice. Am J Respir Crit Care Med 1997, 155:1890-1894.
16. Filep JG, Fournier A, Földes-Filep E: Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors. Br J Pharmacol 1995, 115:227-236.
17. Langleben D, DeMarchie M, Laporta D., Spanier AH, Schlesinger RD, Stewart DJ: Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. Am RevRespir Dis 1993, 148:1646-1650.
18. Finsnes F, Skjønsberg OH, Tønnessen T, Naess O, Lyberg T, Christensen G: Endothelin production and effects of endothelin antagonism during experimental airway inflammation. Am J Respir Crit Care Med 1997, 155:1404-1412.
19. Glaucer MP, Zanetti G, Baumgartner J-D, Cohen J: Septic shock: Pathogenesis. Lancet 1991, 338:732-739.
20. Hewett JA, Roth RA: Hepatic and extrahepatic pathology of bacterial lipopolysaccharides. Pharmacol Rev 1993, 45:381-411
21. Fink MP, Heard SO: Laboratory models of sepsis and septic shock. J Surg Res 1990, 49:186-196.
22. Repine JE: Scientific perspectives on adult respiratory distress syndrome. Lancet 1992, 339:466-472.
23. Fulkerson WJ, MacIntyre N, Stamler J., Crapo JD: Pathogenesis and treatment of the adult respiratory distress syndrome. Arch Intern Med 1996,156:29-38
24. Pan C, Wang J, Liu W., Liu L, Jing L, Yang Y., Qiu H: Low tidal volume protects pulmonary vasomotor function from "second-hit" injury in acute lung injury rats. Respir Res 2012,13:77.
25. Brigham KL, Meyrick B: Endotoxin and the lung. Am Rev Respir Dis 1986, 133:913-927.
26. Williams TJ, Yarwood H: Effect of glucocorticoids on microvascular permeability. Am Rev Respir Dis 1990,141:39-43
27. Suntres ZE, Shek PN: Prophylaxis against lipopolysaccharide-induced lung injuries by liposome-entrapped dexamethasone in rats. Biochem Pharmacol 2000, 59:1155-1161
28. Huribal M, Kumar R, Cunningham M.E., Sumpio BE, McMillen MA: Endothelin-stimulated monocyte supernatants enhance neutrophil superoxide production. Shock 1994, 1:184-187
29. Trabold B, Pawlik M, Nietsch R., Bitzinger DI, Gruber M, Ittner KP, Lubnow M: Bosentan reduces oxidative burst in acid aspiration-induced lung injury in rats. Injury 2009, 40:946-949.
30. Gamze K, Mehmet HM, Deveci F, Turgut T., Ilhan F, Ozercan I: Effect of bosentan on the production of proinflammatory cytokines in a rat model of emphysema. Exp Mol Med 2007, 39:614-620
31. Matute-Bello G., Frevert CW, Martin TR: Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008, 295:379-399.